AzurRx BioPharma, Inc.
AZRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $7 | $11 | $16 | $9,056 |
| G&A Expenses | $928 | $628 | $806 | $3,474 |
| SG&A Expenses | $928 | $628 | $806 | $3,474 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $935 | $639 | $821 | $12,530 |
| Operating Income | -$935 | -$639 | -$821 | $1,873 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$218 | -$359 | -$438 | -$2,962 |
| Pre-Tax Income | -$1,153 | -$998 | -$1,260 | -$1,089 |
| Tax Expense | $0 | $0 | $0 | -$1,736 |
| Net Income | -$1,153 | -$998 | -$1,260 | $31,577 |
| % Margin | – | – | – | – |
| EPS | -0.75 | -0.21 | -0.28 | -2.75 |
| % Growth | -257.1% | 25% | 89.8% | – |
| EPS Diluted | -0.75 | -0.21 | -0.28 | -2.75 |
| Weighted Avg Shares Out | 1,653 | 4,765 | 4,765 | 3,435 |
| Weighted Avg Shares Out Dil | 1,653 | 4,765 | 4,765 | 3,435 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | -$36 | $36 | $18 | $1,211 |
| Depreciation & Amortization | $0 | $0 | $0 | -$407 |
| EBITDA | -$935 | -$639 | -$821 | -$4,443 |
| % Margin | – | – | – | – |